Artrya (ASX:AYA) submitted its response to the US Food and Drug Administration's queries about its regulatory approval application for its Salix coronary anatomy product, according to a Friday Australian bourse filing.
The technological product uses deep-learning algorithms to predictively diagnose potential acute coronary events, the company informed in an earlier filing.
The company did not specify the nature of the queries.
The company's shares rose 2% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.